Related Experiment Video

Updated: Aug 11, 2026

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia

Mariela B Monreal1, Maria L Pardo, Miguel A Pavlovsky

  • 1FUNDALEU (Foundation to Fight Leukemia) and Centro de Investigacion Clinica A. Ocampo, Buenos Aires, Argentina. citometria@fundaleu.org.ar

Cytometry. Part B, Clinical Cytometry
|February 14, 2006
PubMed
Abstract

Insights

Increased immature hematopoietic progenitor cells (HPCs) in high-risk myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (AML) indicate blocked stem cell differentiation. This finding aids in understanding disease progression and risk stratification.

Area of Science:

  • Hematology
  • Cell Biology
  • Immunophenotyping

Background:

  • Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders impacting hematopoietic progenitor cells (HPCs).
  • Phenotypic analysis of clonal CD34+ cells in MDS is crucial for understanding differentiation abnormalities.
  • Abnormalities in HPC differentiation are implicated in MDS pathogenesis.

Purpose of the Study:

  • To evaluate phenotypic changes in HPCs in MDS patients.
  • To assess CD38 and HLA-DR expression on CD34+ cells to identify abnormalities in stem cell differentiation.
  • To correlate HPC phenotypes with disease risk and progression.

Main Methods:

  • Flow cytometry was used to analyze CD38 and HLA-DR expression on CD34+ cells.
  • The study included 36 MDS patients, 12 healthy donors, and various hematological disorder patient groups.
  • International Prognostic Scoring System (IPSS) risk groups were used for analysis of cases with available karyotype.

Main Results:

  • A significant increase in immature HPCs (CD34+bright, CD38dim) was observed in high-risk MDS and secondary AML compared to normal bone marrow.
  • Low-risk MDS and de novo AML showed no significant increase or a decrease in immature HPCs, respectively.
  • Higher numbers of immature HPCs correlated with higher IPSS risk groups and impacted disease progression.

Conclusions:

  • CD38 expression analysis on HPCs is a reproducible method to quantify immature progenitor cells.
  • Elevated immature HPCs in high-risk MDS and secondary AML suggest a block in CD34+ cell differentiation.
  • This immunophenotypic evaluation aids in understanding MDS and AML pathogenesis.

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Production of Formed Elements01:34

Production of Formed Elements

Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...